Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

This is a combination study of Tebentafusp and the PI3Kdelta inhibitor, Roginolisib

Trial Details

NCT ID
NCT07203391
Phase
PHASE1
Sponsor
St Vincent's Hospital, Sydney
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • roginolisib
Locations (sample)
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Melbourne, Victoria, Australia|-37.814,144.96332

Key Eligibility Criteria

  • Male or female participants must be aged 18 years or over at the time, to be eligible to participate in this study.
  • Histologically or cytologically confirmed metastatic UM or unresectable UM patients
  • HLA-A\*02:01 positive
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →